Amidst a grave economical crisis, the pioneer Greek Pharmaceutical Industry managed to maintain and increase its personnel, which currently numbers 948 people across the entire Group. Moving against harsh financial circumstances, ELPEN proceeded with recruitments in key sectors, in the fields of Research & Development, exports and production.
Mr. Theodore Tryfon, Vice President of ELPEN’s Board of Directors, and President of the Panhellenic Union of Pharmaceutical Industry (PEF), received the award. Mr. Tryfon mentioned: «Today, ELPEN is one of the most dynamic Greek companies that support our national economy and the pharmaceutical business on the whole. Within this context, we constantly invest in research programs, aiming at developing drugs of high quality and therapeutic value.» He also added: «ELPEN has a specific business plan for the future – a plan, which the company will pursue with the same devotion, contributing to our country’s exit from the crisis, ensuring unhampered patient access to quality drugs and internationally promoting a healthy business standard.»
Concluding his public statement, Mr. Tryfon noted: «One out of three drugs is currently given by pharmaceutical companies to the State, with essentially no cost – that is, for free. This clearly demonstrates the social role of pharmaceutical companies. We will continue to do so, yet it is crucial for this contribution to take place according to specific rules, within a specific time frame and in a specific manner. This is, in fact, the big challenge for the future. It is precisely for this reason that we, collectively as a sector, fight to set the framework of structural measures, in order to modernize the system and allow the pharmaceutical industry to continue investing, offering added value to Greece, creating jobs and, of course, generating significant research and protocols for products that will be equal of those produced by foreign companies.”